Country: United States
Language: English
Source: NLM (National Library of Medicine)
CAPTOPRIL (UNII: 9G64RSX1XD) (CAPTOPRIL - UNII:9G64RSX1XD)
Physicians Total Care, Inc.
CAPTOPRIL
CAPTOPRIL 12.5 mg
ORAL
PRESCRIPTION DRUG
Captopril Tablets, USP are indicated for the treatment of hypertension. In using Captopril Tablets, USP consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS ). Captopril Tablets, USP may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril Tablets, USP are effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Captopril Tablets, USP are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require
Captopril Tablets, USP are available as follows: 25 mg - White, Round Tablets; Debossed "WW 172" on one side and Quadrisect Scored on the other side. 50 mg - White, Oblong Tablets; Debossed "WW 173" on one side and Scored on the other side. All Captopril Tablets, USP are white and may exhibit a slight sulfurous odor. Store at 20-25°C (68-77°F) [See USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. Manufactured by: West-Ward Pharmaceutical Corp. Eatontown, NJ 07724 Revised January 2012 Distributed and Repackaged by: Physicians Total Care, Inc. Tulsa, Oklahoma 74146
Abbreviated New Drug Application
CAPTOPRIL - CAPTOPRIL TABLET PHYSICIANS TOTAL CARE, INC. ---------- CAPTOPRIL TABLETS, USP REV. 01/12 RX ONLY USE IN PREGNANCY WARNING: FETAL TOXICITY ·WHEN PREGNANCY IS DETECTED, DISCONTINUE CAPTOPRIL AS SOON AS POSSIBLE. ·DRUGS THAT ACT DIRECTLY ON THE RENIN-ANGIOTENSIN SYSTEM CAN CAUSE INJURY AND DEATH TO THE DEVELOPING FETUS. SEE WARNINGS: FETAL TOXICITY DESCRIPTION Captopril Tablets, USP are a specific competitive inhibitor of angiotensin I-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I to angiotensin II. Captopril is designated chemically as 1-[(2S)-3-mercapto-2-methylpropionyl]-L-proline and has the following structural formula: MW=217.29 C H NO S Captopril is a white to off-white crystalline powder that may have a slight sulfurous odor; it is soluble in water (approx. 160 mg/mL), methanol, and ethanol and sparingly soluble in chloroform and ethyl acetate. Each tablet, for oral administration, contains 12.5 mg, 25 mg, 50 mg, or 100 mg of captopril. In addition, each tablet contains the following inactive ingredients: anhydrous lactose, colloidal silicon dioxide, microcrystalline cellulose, sodium starch glycolate, starch, and stearic acid. CLINICAL PHARMACOLOGY MECHANISM OF ACTION The mechanism of action of captopril has not yet been fully elucidated. Its beneficial effects in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin- aldosterone system. However, there is no consistent correlation between renin levels and response to the drug. Renin, an enzyme synthesized by the kidneys, is released into the circulation where it acts on a 9 15 3 plasma globulin substrate to produce angiotensin I, a relatively inactive decapeptide. Angiotensin I is then converted by angiotensin converting enzyme (ACE) to angiotensin II, a potent endogenous vasoconstrictor substance. Angiotensin II also stimulates aldosterone secretion from the adrenal cortex, thereby contributing to sodium and fluid retention. Captopril prevents the conversion Read the complete document